BioXcel Therapeutics (BTAI) Depreciation & Amortization (CF) (2017 - 2022)

BioXcel Therapeutics has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $77000.0 in Q1 2022.

• On a quarterly basis, Depreciation & Amortization (CF) rose 18.46% year-over-year to $77000.0 in Q1 2022; TTM through Dec 2022 was $77000.0, a 74.07% decrease from a year earlier, with the FY2021 full-year figure at $297000.0, up 57.98% from the prior year.
• Depreciation & Amortization (CF) was $77000.0 for Q1 2022 at BioXcel Therapeutics, up from $76000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $96000.0 in Q3 2019, with the low at -$62000.0 in Q4 2019.
• Average Depreciation & Amortization (CF) over 5 years is $48733.3, with a median of $47000.0 recorded in 2020.
• The largest YoY upside for Depreciation & Amortization (CF) was 1271.43% in 2019 against a maximum downside of 875.0% in 2019.
• Over 5 years, Depreciation & Amortization (CF) stood at $8000.0 in 2018, then plunged by 875.0% to -$62000.0 in 2019, then surged by 172.58% to $45000.0 in 2020, then surged by 68.89% to $76000.0 in 2021, then climbed by 1.32% to $77000.0 in 2022.
• The last three Depreciation & Amortization (CF) figures came in at $77000.0 (Q1 2022), $76000.0 (Q4 2021), and $76000.0 (Q3 2021), per Business Quant data.